November 20, 2024 2 min watch NEW YORK — In this Healio Video Perspective from OSN New York, William B. Trattler, MD, of the Center for Excellence in Eye Care in Miami, discusses how the EVO ICL may be beneficial for patients with keratoconus and myopia. Trattler shared a case in which a high myope with keratoconus experienced improvements in visual acuity and … [Read more...] about VIDEO: Consider EVO ICL for high myopes with keratoconus
News
VIDEO: Experts debate anatomic vs. functional benefits of therapies for dry AMD
Source: Healio Interviews Disclosures: Csaky reports consulting for AbbVie, Annexon Biosciences, Astellas, Boehringer Ingelheim Pharmaceuticals, Cognition Therapeutics, EyeBio, F. Hoffmann-La Roche AG, Genentech, Johnson & Johnson Health Care Systems, Merck, NGM Biopharmaceuticals, Novartis and Regeneron Pharmaceuticals and serving in a data and safety monitoring role for … [Read more...] about VIDEO: Experts debate anatomic vs. functional benefits of therapies for dry AMD
FDA grants rare pediatric disease, fast track designations to Stargardt disease therapy
November 20, 2024 1 min read Key takeaways: Gildeuretinol, an oral therapy for Stargardt disease, received rare pediatric disease and fast track designations from the FDA. The designations are backed by positive safety and efficacy findings. The FDA granted rare pediatric disease and fast track designations to gildeuretinol, an investigational oral therapy for the … [Read more...] about FDA grants rare pediatric disease, fast track designations to Stargardt disease therapy
Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
Melt Pharmaceuticals Inc. today announced positive topline results from its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.According to the company, based on a Special Protocol Assessment agreement with the FDA earlier this year, the study design and … [Read more...] about Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
Innovation and the clinician-scientist
Innovation in ophthalmology often arises from unexpected sources, driven by collaboration between researchers and clinicians. Here, 2 pioneering clinician-scientists specializing in the cornea share their insights on the origins of their innovations, the journey to realization, and the essence of being a clinician-scientist.Edward J. Holland, MD: The seed of innovation often … [Read more...] about Innovation and the clinician-scientist
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-friendly, multispecialty CME ophthalmology conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times' Sheryl Stevenson, group editorial director - eye care, to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San … [Read more...] about Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
European Commission approves Opuviz as aflibercept biosimilar
November 19, 2024 1 min read Key takeaways: Opuviz was approved in Europe for wet AMD and vision loss related to other retinal conditions. It is the second European-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnership. The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing … [Read more...] about European Commission approves Opuviz as aflibercept biosimilar
Study of atropine-based myopia treatment fails to meet primary efficacy endpoint
November 19, 2024 1 min read Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release. “We are disappointed that the [Data Review Committee (DRC)] determined that the CHAPERONE study does … [Read more...] about Study of atropine-based myopia treatment fails to meet primary efficacy endpoint
VIDEO: ONL1204 has different approach for treatment of geographic atrophy
November 19, 2024 1 min watch CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses study results presented at the AAO meeting on ONL1204 from ONL Therapeutics. “It’s a very different approach, really more of a neuroprotective approach for [geographic atrophy] and that I think is kind of exciting,” Miller said. Published … [Read more...] about VIDEO: ONL1204 has different approach for treatment of geographic atrophy
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class investigational candidate, topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. At the same time, Aldeyra is choosing to expand their option agreement with AbbVie, granting the manufacturer more cash to bring the drug to … [Read more...] about FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye